TWi Biotechnology, Inc (6610) Fair Value & Analysis
Healthcare · TW · Market cap 5.6B TWD
Fair value as of: Jul 21, 2026
From 1 valuation models · updated 20 days ago
Share price −6.9% over the past month.
Below-average quality, and screening another 13% overvalued on our models.
What matters now
- A fairly wide model range (15.39 TWD to 29.13 TWD) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (8 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 21, 2026.
How to read this chart
8‑month range 15.55 TWD – 32.40 TWD · fair‑value band 15.39 TWD – 29.13 TWD · the 26.55 TWD price screens above the 23.09 TWD fair value. As of Jul 21, 2026.
Analysis
TWi Biotechnology, Inc (6610) currently trades at 26.55 TWD, while our model-based Fair Value estimate is 23.09 TWD, implying the stock looks roughly 13.1% overvalued today. The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
It earns a return on equity of -28.1%. The balance sheet holds a net cash position of 111M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 15.39 TWD (bear case) to 29.13 TWD (bull case); at 26.55 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 76% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -13%, 6610 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 6610 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 35 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan.
Full company description
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
TWi Biotechnology, Inc reported revenue of 0 TWD in FY2025 versus 66.4M TWD in FY2021. Reported net income was −358M TWD in FY2025.
6610 screens 13% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare TWi Biotechnology, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TWi Biotechnology, Inc (6610) overvalued or undervalued?
What is the fair value of 6610?
What is the quality score of 6610?
What is the net profit margin of 6610?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track TWi Biotechnology, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.